Inventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume – Here’s Why

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) shares saw unusually-strong trading volume on Thursday . Approximately 174,831 shares were traded during trading, an increase of 151% from the previous session’s volume of 69,777 shares.The stock last traded at $3.8110 and had previously closed at $4.05.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a report on Wednesday, October 8th. Canaccord Genuity Group restated a “buy” rating and issued a $20.00 target price on shares of Inventiva in a research note on Tuesday, September 30th. HC Wainwright increased their price target on shares of Inventiva from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Thursday, October 9th. Wall Street Zen raised Inventiva to a “hold” rating in a report on Saturday, October 18th. Finally, Guggenheim upped their price target on shares of Inventiva from $9.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, September 2nd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Inventiva presently has an average rating of “Moderate Buy” and an average price target of $17.57.

Inventiva Price Performance

The firm’s 50-day moving average price is $5.24 and its 200 day moving average price is $4.18.

Institutional Trading of Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Creative Planning acquired a new stake in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 10,000 shares of the company’s stock, valued at approximately $32,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.